There’s a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Veeva Systems (VEEV – Research Report) and Nutanix (NTNX – Research Report) with bullish sentiments.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Veeva Systems (VEEV)
In a report released today, Kenneth Wong from Guggenheim maintained a Buy rating on Veeva Systems, with a price target of $255.00. The company’s shares closed last Wednesday at $230.62.
According to TipRanks.com, Wong is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Veeva Systems with a $271.30 average price target, a 16.9% upside from current levels. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $290.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Nutanix (NTNX)
In a report released today, Mike Cikos from Needham maintained a Buy rating on Nutanix, with a price target of $34.00. The company’s shares closed last Wednesday at $27.26.
According to TipRanks.com, Cikos is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nutanix with a $40.00 average price target, a 49.8% upside from current levels. In a report issued on February 23, J.P. Morgan also maintained a Buy rating on the stock with a $50.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VEEV:
- PLBY Group (PLBY) Gets a Buy Rating from Chardan Capital
- H.C. Wainwright Sticks to Their Buy Rating for PMV Pharmaceuticals (PMVP)
- Rush Street Interactive (RSI) Gets a Buy Rating from Needham
- Relay Therapeutics (RLAY) Receives a Buy from H.C. Wainwright
- H.C. Wainwright Thinks Repare Therapeutics’ Stock is Going to Recover